Samsung Epis Holdings Q1 2026: Profit Intact, Cash Bleeds ₩315.6B
A biosimilar holdco's debut full quarter: a 20% operating margin obscures a ₩315.6 billion operating cash deficit funded entirely by new short-term bank debt.
Source: Q1 2026 Quarterly Report (Period 2, Q1) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Samsung Epis Holdings Q1 2026: Profit Intact, Cash Bleeds ₩315.6B”
This article became available on June 7, 2026. Subscribe to read in full, or wait until September 5, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
You just read what happened. Here's how to read what it means.
We read this company's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox in 30–40 min.
$12 · one-time
Get the full reportReading several Korean stocks a week? Get on-demand analysis on any KOSPI or KOSDAQ company, whenever you need it.
$9.99 · monthly
SubscribeIndependent journalism based on primary DART filings — not investment advice. No brokerage affiliation.
